We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.

Science

Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Month: July 2015

  • ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program

    ONL Therapeutics Promotes New Lead Drug, Expands Clinical Program Xconomy Detroit – 7/6/15 by Sarah Schmid ONL Therapeutics, a University of Michigan spin-out working on sight-preserving therapies for retinal diseases, announced that it has changed course in its drug development program. The company has promoted a new lead drug candidate and has expanded its planned clinical studies to…